Skip to main content
. 2008 Jun;3(2):211–225.

Table 1.

Summary of included studies

Drug(s) Study Daily dosea Duration (weeks) Baseline MMSE Outcomeb
 Quality rating
Cognition Function Behavior Global
Donepezil(D) vs. Galantamine(G) Jones et al 2004 (D) 5–10 mg
(G) 8–24 mg		 12 10–24 ADAS-cog DAD – – NAc
Wilcock et al 2003 (D) 5–10 mg
(G) 16–24 mg		 52 9–18 ADAS-cog BADLS NPI – NAc
Donepezil(D) vs.Rivastigmine(R) Bullock et al 2005 (D) 5–10 mg
(R) 3–12 mg		 104 10–20 – ADCS/ADL NPI – Good
Wilkinson et al 2002 (D) 5–10 mg
(R) 6–12 mg		 12 10–26 ADAS-cog – – – NAc
Donepezil AD2000 Collaborative, 2004 5–10 mg 60 10–27 – BADLS NPI – Fair
Burns et al 1999 5–10 mgd 24 10–26 – IDDD – CIBIC+ Fair
Feldman et al 2001 5–10 mg 24 5–17 – DAD NPI – Good
Homma et al 2000 5 mg 24 10–26 ADAS-Jcog CMCS – CGI-C Fair
Mohs et al 2001 10 mg 54 12–20 – ADFACS – – Fair
Rogers et al 1998a 5–10 mgd 12 10–26 ADAS-cog – – CIBIC+ Fair
Rogers et al 1998b 5–10 mgd 24 10–26 ADAS-cog – – CIBIC+ Fair
Rogers and Friedhoff 1996 5 mgd 12 10–26 ADAS-cog – – CGI-C Fair
Seltzer et al2004 10 mg 24 21–26 ADAS-cog – – – Fair
Tariot et al 2001 5–10 mg 24 5–26 – – – NPI Fair
Winblad et al 2001 10 mg 52 10–26 – PDS – – Fair
Winblad et al 2006 10 mg 24 1–10 – ADCS/ADL NPI CGI-C Fair
Galantamine Brodaty et al 2005e 16–24 mg 26 10–24 ADAS-cog ADCS/ADL NPI CIBIC+ Good
Raskind et al 2000 24 mgd 24 11–24 ADAS-cog – – CIBIC+ Fair
Rockwood et al 2001 24–32 mg 12 11–24 ADAS-cog DAD – CIBIC+ Fair
Rockwood et al 2006 24 mg 16 10–25 ADAS-cog – NPI – Fair
Tariot et al 2000 16–24 mgd 20 10–22 ADAS-cog ADCS/ADL NPI – Fair
Wilcock et al 2000 24 mg 24 11–24 ADAS-cog DAD – CIBIC+ Good
Wilkinson and Murray 2001 18–24 mgd 12 13–24 ADAS-cog – – CGI-C Fair
Rivastigmine Agid et al 1998 6 mg 13 NRf – NOSGER – – Fair
Corey-Bloom et al 1998 6–12 mg 26 10–26 ADAS-cog PDS – CIBIC+ Fair
Rosler et al 1999 6–12 mg 26 10–26 ADAS-cog PDS – CIBIC+ Fair
a

Notes: Fixed doses outside of the range of the manufacturer label excluded; flexible dosing studies might allow doses outside of labeled range;

b

Does not indicate whether the outcome was primary or secondary in the trial design, and some outcomes were not reported or abstracted;

c

Not applicable; open-label trials were not rated for quality;

d

Value reflects fixed dosing design (compared with flexible dosing);

e

Galantamine and Galantamine Prolonged-Release Capsule (PRC);

f

DSM-III-R mild-to-moderate dementia.

Abbreviations: MMSE, Mini Mental State Exam; ADAS-cog, Alzheimer’s Disease Assessment Scale-Cognitive section; ADAS-Jcog, Japanese translation of ADAS-cog; SIB, Severe Impairment Battery; CGI-C, Clinical Global Impression of Change; ADCS/ADL, Alzheimer’s Disease Cooperative Studies Activities of Daily Living Inventory; ADFACS, Alzheimer’s Disease Functional Assessment and Change Scale; BADLS, Bristol Activities of Daily Living Scale; CMCS, Caregiver-rated Modified Crichton Scale; DAD, Disability Assessment for Dementia; IDDD, Interview for Deterioration in Daily living activities in Dementia; NOSGER-IADL, Nurses Observation Scale for Geriatric Patients Activities of Daily Living; PDS, Progressive Deterioration Scale; CIBIC+, Clinician Interview-Based Impression of Change Incorporating Caregiver Information.